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Abstract: Serelaxin (RLX) designates the pharmaceutical form of the human natural hormone
relaxin-2 that has been shown to markedly reduce tissue and cell damage induced by hypoxia and
reoxygenation (HR). The evidence that RLX exerts similar protective effects on different organs
and cells at relatively low, nanomolar concentrations suggests that it specifically targets a common
pathogenic mechanism of HR-induced damage, namely oxidative stress. In this study we offer
experimental evidence that RLX (17 nmol L-1), added to the medium of HR-exposed H9c2 rat cardiac
muscle cells, significantly reduces cell oxidative damage, mitochondrial dysfunction and apoptosis.
These effects appear to rely on the up-regulation of the cellular availability of reduced glutathione
(GSH), a ubiquitous endogenous antioxidant metabolite. Conversely, superoxide dismutase activity
was not influenced by RLX, which, however, was not endowed with chemical antioxidant properties.
Taken together, these findings verify the major pharmacological role of RLX in the protection against
HR-induced oxidative stress, and shed first light on its mechanisms of action.
Keywords: relaxin; serelaxin; cardiac muscle cells; ischemia-reperfusion; hypoxia–reoxygenation;
oxidative stress
1. Introduction
Serelaxin (RLX; synonyms: recombinant human relaxin, rhRLX) designates the pharmaceutical
form of the human natural hormone relaxin-2 (RLX-2; H2 RLX) suitable for clinical use. In recent years,
robust evidence has been accumulating that RLX can markedly reduce tissue and cell damage induced
by ischemia and reperfusion (IR) [1–3]. Such a protective effect has been consistently observed in diverse
experimental models, spanning from organ IR in whole animals (heart, gut, kidney) [4–8] and in isolated
and perfused organs (heart, lung, liver) [9–12] to specific cell types (cardiomyocytes, trophoblast)
subjected to in vitro hypoxia (associated or not with nutrient starvation) and reoxygenation [13,14].
The fact that RLX exerts similar protective effects on different organs and cells at relatively low
concentrations (in the nanomolar range) suggests that this molecule specifically targets a common
pathogenic mechanism of the IR-induced damage.
The interplaying events occurring upon IR mainly involve oxidative stress. In fact,
the dysfunctional mitochondria of cells under hypoxia show impaired electron flow and an enhanced
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formation and release of superoxide anion (O2•−) [15]. Moreover, at low O2 concentrations,
the mitochondrial respiratory chain also generates nitric oxide (NO•) by nitrite reduction [16]. The O2•−
and NO• generated under hypoxia promptly react to peroxynitrite (ONOO−) [17], which is regarded
as the major harmful oxidant in IR damage [18]. In vivo, these mitochondrial mechanisms of oxidative
stress are paralleled by inflammatory cell recruitment secondary to endothelial injury [19], which results
in the further enhancement of ONOO− generation. Of note, ONOO− is held responsible for most,
if not all, of the detrimental effects of excess NO• [18,20].
The current study was designed to investigate whether the well-known protective action of
RLX against IR-induced damage may be related to a beneficial redox balancing effect on target cells.
To this purpose, we used a typical in vitro cellular model of hypoxia–reoxygenation (HR), equivalent
to in vivo or ex vivo organ IR, on previously and successfully exploited H9c2 cardiac myoblasts,
to demonstrate the cardioprotective role of RLX [13].
2. Materials and Methods
2.1. Cell Culture
H9c2 embryonic rat cardiac muscle cells, obtained from the European Collection of Cell Cultures
(ECACC, Salisbury, UK), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% heat-inactivated fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA), 2 mmol L−1
glutamine, 250 U mL−1 penicillin G and 250 µg mL−1 streptomycin, in a humidified atmosphere
with 5% CO2 at 37 ◦C. The H9c2 cells were subjected to hypoxia and reoxygenation (HR) as
previously described [13]. Hypoxic challenge was achieved by using a modular incubator chamber
(Billups-Rothenberg, Inc., San Diego, CA, USA) gassed with 95% N2 and 5% CO2. A flow meter was
used to measure the quantity of gas mixture introduced into the chamber (25 L min−1). To simulate IR,
after incubation under hypoxic conditions and in serum and glucose-free medium for 7 h, the cells were
reoxygenated via the immediate replacement of fresh complete culture medium, and were returned
to a normoxic environment at 37 ◦C for 60 min. Cell treatment was induced 24 h before the hypoxic
challenge and at the moment of reoxygenation by adding RLX at concentrations of 17 nmol L−1 [15].
This RLX concentration was similar to that previously found to protect H9c2 cells from HR-induced
injury [13]. The experiments were performed in triplicate.
2.2. Intracellular ROS and Mitochondrial O2•−
The ROS-sensitive fluorescent probe 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA,
2.5 µmol L−1, Invitrogen, CA, USA) or the mitochondrial O2•−-specific fluorescent probe MitoSOX
(3 µmol L−1, Invitrogen) dissolved in 0.1% DMSO and 0.01% w/v Pluronic acid F-127 were added to
H9c2 cells seeded on glass coverslips for 15 min at 37 ◦C, as previously described [13]. Cells were
fixed at room temperature for 10 min in 2% buffered paraformaldehyde and fluorescence analyzed
using a Leica TCS SP8 confocal scanning microscope equipped with an argon laser source (excitation
λ 488 nm or 543 nm, respectively) and a 63× oil immersion objective. ROS and mitochondrial O2•−
production were also estimated by flow cytometry [21]: briefly, single-cell suspensions were incubated
with H2DCFDA (1 µmol L−1) or MitoSOX (0.5 µmol L−1) for 15 min at 37 ◦C, and immediately analyzed
under a FACSCantoII flow cytometer (Becton–Dickinson) [22]. Data were analyzed using FACSDiva
software (Becton Dickinson, San Jose, CA, USA).
2.3. Evaluation of Lipid Peroxidation
Lipid peroxidation, a reliable oxidative stress index, was assayed by confocal scanning microscopy
using BODIPY 581/591 C11 (Life Technologies, Carlsbad, CA, USA), a lipophilic fluorescent probe
that mimics the properties of natural lipids [13]. In the presence of oxidizing agents, BODIPY 581/591
C11 shifts its fluorescence from red to green. Cells, cultured on glass coverslips, were loaded with
BODIPY dissolved in 0.1% DMSO (2.5 µmol L−1 final concentration) for 15 min at 37 ◦C in DMEM. Cells
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were then fixed in 2.0% buffered paraformaldehyde for 10 min at room temperature and fluorescence
estimated using a confocal Leica TCS SP8 scanning microscope equipped with an argon laser source
for fluorescence measurements. A series of optical sections (1024 × 1024 pixels) 1.0 µm in thickness
was taken throughout the cell depth at intervals of 0.5 µm using a Leica Plan Apo 63× oil immersion
objective and then projected as a single composite image by superimposition. Lipid peroxidation was
also quantified by flow cytometry on single-cell suspensions incubated (30 min, 37 ◦C in the dark)
with BODIPY 581/591 (2.5 µmol L−1) in DMEM, washed, resuspended in PBS and analyzed under a
FACSCantoII flow cytometer (Becton Dickinson, San Jose, CA, USA).
2.4. Mitochondrial Activity
This was assayed by the resazurin reduction method (CellTiter-Blue, Promega Corp., Madison,
WI, USA), based on the ability of metabolically active cells to reduce resazurin to resorufin and
dihydroresorufin proportionally to their number [23]. Conversion occurs intracellularly and is
facilitated by mitochondrial, microsomal and cytosolic oxido-reductases. Resorufin produced by
resazurin bioreduction was measured fluorometrically. Resazurin is not toxic to cells and maintains its
stability in culture medium, allowing reliable measurements.
2.5. Mitochondrial Membrane Potential (∆ψ)
Tetramethylrhodamine methyl ester perchlorate (TMRM), a lipophilic fluorescent dye, accumulates
in mitochondria as a function of mitochondrial membrane potential ∆ψ [24]. For confocal microscopy,
H9c2 cells were cultured on glass coverslips and loaded for 20 min at 37 ◦C with TMRM, and dissolved
in 0.1% DMSO to a 100 nmol L−1 final concentration in the culture medium. The cells were fixed in
2% buffered paraformaldehyde for 10 min at room temperature, and the TMRM fluorescence was
analyzed under a confocal Leica TCS SP8 scanning microscope equipped with a helium-neon laser
source and a 63× oil immersion objective. ∆ψ was also quantified by flow cytometry on single-cell
suspensions, washed twice with phosphate-buffered saline (PBS) and incubated for 20 min at 37 ◦C in
the dark with TMRM dissolved in DMEM (100 nmol L−1). The cells were then rinsed, resuspended in
PBS and analyzed under a FACSCantoII flow cytometer (Becton Dickinson).
2.6. Mitochondrial Transition Pore Opening (mPTP)
Mitochondrial permeability by transition pore opening is an index of mitochondrial dysfunction
and early apoptosis. This was measured by the calcein fluorescence method [25], based on the
principle that the fluorescent probe calcein-AM readily enters into cells and emits fluorescence upon
de-esterification. The co-loading of cells with cobalt chloride, which cannot cross the mitochondrial
membranes in living cells, quenches calcein fluorescence in the whole cell except mitochondria. During
the induction of mPTP, cobalt can enter mitochondria and quenches calcein fluorescence, the decrease in
which can be taken as a measure of the extent of mPTP induction. H9c2 cells grown on glass coverslips
were loaded with calcein-AM (3 µmol L−1) and cobalt chloride (1 m mol L−1) for 20 min at 37 ◦C in
DMEM. Following washing with PBS and fixation in 2% buffered paraformaldehyde for 10 min at
room temperature, the cells were analyzed under a Leica TCS SP8 confocal laser scanning microscope
equipped with an argon laser source (excitation λ 488 nm) and a 63× oil immersion objective. mPTP was
also estimated by flow cytometry on single-cell suspensions incubated with calcein-AM (3 µmol L−1)
and cobalt chloride (1 mmol L−1) for 20 min at 37 ◦C, washed twice with PBS and analyzed under a
FACSCantoII flow cytometer (Becton Dickinson).
2.7. Caspase Activity
Since mitochondrial dysfunction triggers the apoptotic pathway, we next investigated the activation
of pro-apoptotic initiator caspases 8 (extrinsic pathway) and 9 (intrinsic pathway), and effector caspase
3, as described [13]. H9c2 cells seeded on glass coverslips were incubated with a FAM-FLICA™
Caspase assay kit (Immunochemistry Technologies, Bloomington, MN, USA) for 30 min, following
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the manufacturer’s instructions. The FLICA reagent enters each cell and irreversibly binds to active
caspases. Any unbound FLICA reagent diffuses out of the cell and is washed away. The remaining
intracellular fluorescent signal is a direct measure of the active caspase enzyme activity present in the
cell. After incubation, the cells were thoroughly washed and fixed in 2% buffered paraformaldehyde
for 10 min at room temperature. Fluorescence was detected by a confocal Leica TCS SP8 scanning
microscope equipped with an argon laser source and a 63× oil immersion objective. Caspase activity
was also quantified by flow cytometry on single-cell suspensions treated with FAM-FLICA™ for 30 min
at 37 ◦C, washed twice with PBS and estimated under a FACSCantoII flow cytometer (Becton Dickinson).
2.8. Cell Death Assay
Lactate dehydrogenase (LDH) activity, an index of cell death, was measured spectrophometrically
in culture medium and in adherent H9c2 cells (to obtain total LDH content) using the LDH assay kit
(Roche Diagnostics, Mannheim, Germany) as previously described [26]. LDH release was calculated as
the percentage of total LDH content.
2.9. Superoxide Dismutase (SOD) Activity
Total SOD activity was measured using the Superoxide Dismutase Colorimetric Activity Kit
(Invitrogen), according to the manufacturer’s protocol. Briefly, H9c2 cells from the different treatments
were sonicated in cold PBS and the supernatant was used for the assay. The reaction was initiated by
adding xanthine oxidase. SOD activity absorbance was measured at 450 nm on an Infinite M200PRO
microplate reader (Tecan Group Ltd., Männedorf, Switzerland) and expressed as U/mg of total
proteins. One unit of SOD is defined as the amount of enzyme causing half the maximum inhibition of
1.5 mmol L−1 blue tetrazolium reduction in the presence of riboflavin at pH 7.8 and 25 ◦C. Total protein
content was measured spectrophotometrically using micro-BCA™ Protein Assay Kit (Pierce, IL, USA).
2.10. Glutathione Levels
To determine the level of intracellular GSH content, H9c2 single-cell suspensions were incubated
in DMEM without serum and phenol red with the glutathione detection reagent ThiolTracker™ Violet
(10 µmol L−1) (ThermoFisher Scientific, Waltham, MA USA), for 30 min at 37 ◦C, washed twice with
PBS, and analyzed immediately by FACS.
2.11. Assay of RLX Antioxidant Properties
Finally, we assayed whether the RLX molecule was intrinsically endowed with chemical antioxidant
properties. To this end, the ORAC (oxygen radical absorbance capacity) method was performed as
previously described [27]. Briefly, fluorescein solution (6 nmol L−1) was freshly prepared daily in
75 mmol L−1 sodium phosphate buffer, pH 7.4, and Trolox (25–100 µmol L−1 final concentration) was
used as a standard. To better reveal its possible antioxidant features, RLX was tested at a 100 µmol L−1
final concentration, which was substantially higher than that used in the other experiments. Seventy
microliters of each sample with 100 µL of fluorescein was pre-incubated for 30 min at 37 ◦C in each well,
before rapidly adding 2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH) solution (19 mmol L−1
final concentration). Fluorescence was measured using a Synergy H1 microplate reader (BioTek,
Winooski, VT, USA). The results were expressed as Trolox equivalents (nmol L−1) and then normalized
for protein concentration.
2.12. Statistical Analysis
Unless otherwise indicated, statistical analysis of the differences between the quantitative values
of the experimental groups was performed by one-way ANOVA and Newman–Keuls post-hoc tests
for multiple comparisons. p < 0.05 was taken as the significance threshold.
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3. Results
3.1. RLX Protects from HR-Induced Cellular Oxidative Stress
RLX (17 nmol L−1) added before hypoxia and at reoxygenation afforded protection to H9c2 cells
by reducing the oxidative stress occurring upon HR, as previously reported [13]. Endogenously
generated ROS, determined by loading the cells with the fluorescent probe H2DCFDA, was decreased
more significantly in the RLX-treated cells than in the untreated control cells (Figure 1A). Similarly,
the evaluation of mitochondrial O2•− generation by the fluorescent probe MitoSOX showed that
RLX significantly reduced O2•−-dependent fluorescence in comparison with the untreated controls
(Figure 1B). We next assessed the peroxidation of cell membrane lipids, a typical detrimental effect of
excess ROS, by the red-to-green fluorescence shift of BODIPY-581/591-C11 lysochrome. In keeping with
the above findings, this oxidative stress parameter was increased by HR and significantly reduced by
RLX (Figure 1C).
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Figure 1. Quantitative evaluation and representative FACS diagrams of cellular oxidative stress 
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O2•− generation, determined by MitoSOX; (C) cell membrane lipid peroxidation, determined by 
BODIPY-581/591-C11. All these parameters of oxidative stress markedly increased upon hypoxia–
reoxygenation (HR), an effect prevented by RLX (17 nmol L−1) added before hypoxia and at 
reoxygenation (AFU: arbitrary fluorescent units). Significance of differences (n = 3): ***p < 0.001 vs. 
controls, +++p < 0.001 vs. HR. 
Figure 1. Quantitative valuation and re tative FACS diagrams of cellular ox dativ tress
assayed by fluoresc nt probes. (A) Endogeno , termined by H2DCFDA; (B) mitochondrial
O2•− generation, determined by itoSOX; (C) cell embrane lipid peroxidation, determined
by BODIPY-581/591-C11. All these parameters of oxidative stress markedly increased upon
hypoxia–reoxygenation (HR), an effect prevented by RLX (17 nmol L−1) added before hypoxia
and at reoxygenation (AFU: arbitrary fluorescent units). Significance of differences (n = 3): *** p < 0.001
vs. controls, +++ p < 0.001 vs. HR.
Representative confocal images of these experiments performed after 1 h reoxygenation are shown
in Figure 2.
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3.2. RLX Improves Cell Mitochondrial ti it I paired by HR
RLX (17 nmol L−1) added poxia and at reoxygenation improved the assayed markers of
the mitochondrial activity of H9c2 cells, hich were markedly impaired by HR-induced oxidative
stress. In fact, the efficiency of the mitochondrial respiratory chain, measured by the fluorescent signal
of reduced resazurin (Figure 3A), and the mitochondrial membrane potential (∆ψ), evaluated by the
inlet of the fluorochrome TMRM (Figure 3B), were markedly reduced by HR and increased significantly
in the RLX-treated cells. We next assayed the opening of transition pores in mitochondrial membranes
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(mPTP) by the extinction of calcein fluorescence (Figure 3C). This sensitive index of mitochondrial
dysfunction and early apoptosis was increased by HR and significantly reduced by RLX.
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transition pore opening (mPTP) determine by calc in extinction. All these parameters of mitochondrial
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by RLX (17 nmol L−1) added before hypoxia and at reoxygenation. (AFU: arbitrary fluorescent units).
Significance of differences (n = 3): *** p < 0.001 vs. controls, +++ p < 0.001 ++ p < 0.01 vs. HR.
Representative confocal images of these experiments performed after 1 h reoxygenation are shown
in Figure 2.
3.3. RLX Protects from HR-Induced Cell Apoptosis
Mitochondrial impairment is known to induce the intrinsic apoptotic pathway operated by the
caspase 9/3 cascade [13]; therefore, we investigated if the protection afforded by RLX to H9c2 cells’
mitochondrial oxidative dysfunction, induced by HR, was accompanied by a reduction of apoptosis.
Compared with the HR-exposed controls, the cells treated with RLX (17 nmol L−1) showed decreased
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activation of pro-apoptotic caspases 9 and 3, while caspase 8, involved in the extrinsic apoptotic
pathway, was substantially unchanged (Figure 4A–C). Consistent with these findings, the evaluation
of cell death by spectrophometric measurement of the LDH activity in the culture medium showed a
marked rise in the HR-exposed controls, which was significantly reduced by RLX (Figure 4D).
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Figure 4. Quantitative evaluation and representative FACS diagrams of cellular apoptosis assayed
by fluorescent probes. The activity of caspase 3 (A) and 9 (B), which are involved in the extrinsic
apoptotic pathway, are markedly increased upon hypoxia–reoxygenation (HR), an effect prevented
by RLX (17 nmol L−1) added before hypoxia and at reoxygenation. On the other hand, caspase 8 (C),
which is involved in the intrinsic apoptotic pathway, is slightly (albeit significantly) increased by HR,
but not substantially affected by RLX. Overall cell death (D), evaluated by LDH release, was also
markedly increased by HR, and reduced by RLX. (AFU: arbitrary fluorescent units). Significance of
differences (n = 3): *** p < 0.001 vs. controls, +++ p < 0.001 vs. HR, n.s. not significant vs. HR.
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Representative confocal images of these experiments performed after 1 h reoxygenation are shown
in Figure 2.
3.4. Possible Mechanisms of the RLX’s Antioxidant Effects
Finally, the possible mechanisms underlying the observed protection by RLX of HR-induced
oxidative stress in H9c2 cells were investigated, starting from the reasoning that they may consist
of (i) the induction of intracellular antioxidant pathways, and/or (ii) the direct antioxidant chemical
properties of the RLX molecule. We first explored whether RLX was able to up-regulate two major
antioxidant endogenous systems, i.e., reduced glutathione (GSH) and superoxide dismutase (SOD).
The measurement of intracellular GSH levels in basal H9c2 cells not subjected to HR showed a marked,
statistically significant increase in the RLX-treated cells as compared with the untreated controls
(Figure 5A). Such RLX-induced GSH increase was even more prominent in the HR-exposed cells
(Figure 5B). Conversely, the assay of SOD activity showed no significant differences between the
RLX-treated and the untreated control cells, exposed or not to HR (Figure 5C). Compared with the
controls, HR caused a slight (albeit significant) decrease in SOD activity (Figure 5C). We then evaluated
by ORAC assay whether the RLX molecule exhibited specific chemical antioxidant activity, and we
found that RLX (100 µmol L−1) displayed no direct antioxidant properties (Figure 6). The calculated
antioxidant capacity of RLX was extremely low, being 0.77 nmol Trolox equivalents µg−1.
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Figure 5. Quantitative evaluation and representative FACS diagrams of cellular antioxidant systems by
fluorescent probes. Levels of reduced glutathione (GSH) in normal cells (A) and in cells subjected to
HR (B), evaluated by ThiolTracker™ Violet. RLX markedly increases intracellular GSH in both normal
and HR-exposed cells. Activity of superoxide dismutase (SOD) in normal cells and in cells subjected to
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n.s. not significant vs. HR.
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mitochondrial function [30]. The present study offers evidence that the cellular mechanisms 
underlying the protection afforded by RLX from HR-induced oxidative stress primarily involves an 
increase in the levels of reduced glutathione (GSH), a ubiquitous cellular antioxidant molecule. Of 
note, this effect of RLX had already manifested in control H9c2 cells not exposed to oxidative stress, 
suggesting that increased GSH bioavailability is a direct and specific action of RLX. This finding is in 
agreement with a previous report that RLX is able to increase GSH levels in H9c2 cells exposed to 
Cobalt chloride-induced oxidative damage [31]. The exact molecular mechanisms linking the 
activation of the RLX receptor and the up-regulation of GSH levels remain to be elucidated, and are 
an interesting matter for future investigations; anecdotal observations suggest the possible 
Figure 6. Assay of the chemical antioxidant properties of RLX. The concentration–response curve
of O2•− abatement in the presence of RLX showed no substantial antioxidant effects, at variance
with increasing concentrations of the known antioxidant Trolox. Significance of differences (two-way
ANOVA; n = 3): RLX vs. Trolox at any concentration, p < 0.001.
4. Discussion
An understanding of the key role of oxidative stress in the pathophysiology of IR is of pivotal
importance in order to highlight the d fensive mechanisms ac ivated by cell and organs, as well as to
dentify eff ctive th rapeutic approaches [28]. Robust experimen al evi ence ha been collected that RLX
protects rom IR- nduc d organ damage, not only beca e of indirect vasodilatory, anti-inflammatory
and anti-fibr ti acti ns, but also via its direct cytoprotective effects, which increase the resistance of
HR-exposed cells to oxygen deprivation and nitroxidative stress [4–12]. The current find ngs fu ther
strengthen and extend our previou reports that RLX blunts IR-induced injury and promotes the survival
of H9c2 cardiac muscle c lls subj c d to HR [13]. They are also in keeping with the observation that
RLX protects cardiomyocytes against oxidative stres -induced ap ptosis [29]. In addition, the findings
demonstrating that HR is associated with mitochondrial dysfunct on, particularly increased O2•−
generation and decr ase membrane potential (∆ψ), support the current view that IR- nduced cellular
d mage involves oxi ative stress initiated by mitochondria [15]. The present findings on H9c2 a diac
muscle cells are in close agreement with those of previous studie on cultured neuroglial cells exposed
to oxidat ve stress indu ed by oxygen and g ucos starvation, which demonstrat d that RLX affor ed
significant cytop tection and the preservation of mi ochondrial functi n [30]. The present study offers
evidence that the cellular mechanisms underlying the protection afforded by RLX from HR-induced
oxidative stress primarily involves an increase in the lev l of re uced glutathione (GSH), a ubiquitou
cellular antioxidant molecule. Of note, this effect of LX had alrea y manifested in control H9c2 cells
not xposed to oxidative stress, sugges ing that increased GSH bioavailability s a irect and sp cific
action of RLX. This finding is in agreement with a previous report that RLX i able to ncrease GSH
levels in H9c2 cells xposed to Cobalt chloride-induc d oxidative damage [31]. The exact molecular
mechanisms linking the activati n of the RLX receptor a d the up-regulation of GSH l vels remain
be elucidated, and are an interes ng m tter for future inv stigations; anecdotal observatio s su gest
the possible involvement of nuclear factor e ythroid 2–related factor 2 (Nrf2), an emerg ng regulator of
cellular istance to oxidants [31]. On th other hand, i our experiment l setup, RLX does not appear
to involve the up-regulation of SOD activity, the key endogenous antioxidant enzymes that catalyze
the dismutation and inactivation of O2•− [32]. This is at variance with previous results obtained
on H9c2 cells subjected to oxidative stress induced by exposure to high glucose [33], in which RLX
appeared to increase MnSOD levels. Notably, in these experiments RLX was added to cells at very high
concentrations (100 nmol mL−1), about 10,000 times higher than those we used in the present study.
The present data also indicate that RLX does not possess intrinsic antioxidant properties. Of note,
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all cysteine residues—whose thiols can behave as reducing groups—that are present in the primary
structure of both A and B RLX chains are involved in the formation of inter- and intra-chain disulfide
bonds [34].
5. Conclusions
In conclusion, this study expands the current knowledge on the pharmacological properties of
RLX as a molecule capable of reducing oxidative stress induced by conditions of oxygen deprivation
followed by re-oxygenation (see graphical abstract). From a clinical perspective, this information
joins the existing experimental background indicating RLX as a possible new drug for the primary
and secondary prevention and therapy of ischemic diseases. Our study was performed using
undifferentiated H9c2 myoblasts, raising questions concerning the relevance of the results obtained
when compared to primary cardiomyocytes. However, in our previous works [13,26,35], we used
a similar HR experimental approach using both H9c2 cardiomyoblasts and primary neonatal rat
ventricular cardiomyocytes, and obtained comparable results. However, future in vivo experiments
are needed to validate the present findings.
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